Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;7(2):136-144.
doi: 10.1016/S2352-4642(22)00314-5. Epub 2022 Dec 13.

Adolescent acne vulgaris: current and emerging treatments

Alison M Layton  1 , Jane Ravenscroft  2
Affiliations
Review

Adolescent acne vulgaris: current and emerging treatments

Alison M Layton et al. Lancet Child Adolesc Health. 2023 Feb.

Abstract

Acne vulgaris is one of the commonest inflammatory skin diseases seen worldwide, affecting all ethnicities and races, with a peak prevalence between age 15 years and 20 years. The burden of this condition, and the resulting clinical and psychological sequelae, is substantial. The visual appearance of acne and its sequelae, including scarring and pigment changes, frequently results in psychological and social morbidity because of concerns about appearance. As understanding of the pathophysiology has evolved, approaches to achieving the optimal outcomes with effective treatment regimens continue to emerge. In the past few years, several novel therapeutics have been developed, including new agents aimed at reducing antimicrobial resistance and products with specific actions targeting retinoid receptors and androgen receptors. This Review considers the management approaches of an adolescent with acne vulgaris and reviews treatment options from the evidence base and international expert opinion. Approaches to selecting current treatments and novel and emerging treatment regimens are discussed.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests AML declares grant funding awarded to her organisation to deliver National Institute for Health and Care Research portfolio studies, including a Health Technology Assessment grant, a British Skin Foundation grant, and Medical Research Council grant. AML received royalties from Wiley for writing a chapter of Acne Fast Facts Series; honoraria for acting as a consultant or attending advisory boards from Galderma Pharma, LEO Pharma, La Roche-Posay, Novartis, and Origimm Biotechnology; and honoraria for unrestricted presentations in educational events and in national and international meetings from Beiersdorf, Galderma Pharma, LEO Pharma, La Roche-Posay, L'Oréal, and Viatris. AML is a member of the British Association of Dermatologists Retinoid Working Group. JR received a small grant award from the UK Dermatology Clinical Trials Network in 2022. JR is an executive committee member of the British Society for Paediatric and Adolescent Dermatology and a member of the British Association of Dermatologists Retinoid Working Group. The authors have no direct competing interests in the writing of this Review and no funding has supported this work.

Substances

LinkOut - more resources